Bioeclipse Therapeutics
Updated: February 24, 2026
CEO Pamela Contag
Country: USA | Funding: $15.7M (+)
Founded: 2006
Website: https://www.bioeclipse.com/
BioEclipse Therapeutics develops targeted immunotherapies against resistant and relapsed solid tumors. Its allogeneic technology harnesses true power of both innate and adaptive immunity for effective treatment. Through its affordable allogeneic (CRX200, IND-ready) and autologous (CRX100, Phase 1b) therapies, BioEclipse has demonstrated the efficacy of targeting the tumor microenvironment of difficult-to-treat solid tumors using living cells programmed to assemble and orchestrate a diverse array of molecules and complex immune pathways. These therapies offer patients the freedom from the apheresis required with each infusion of other cell-based therapies; they also offer more efficient tumor cell killing in a single infusion, reducing the number of infusions and the cell dose and payload.
Founded: 2006
Website: https://www.bioeclipse.com/
BioEclipse Therapeutics develops targeted immunotherapies against resistant and relapsed solid tumors. Its allogeneic technology harnesses true power of both innate and adaptive immunity for effective treatment. Through its affordable allogeneic (CRX200, IND-ready) and autologous (CRX100, Phase 1b) therapies, BioEclipse has demonstrated the efficacy of targeting the tumor microenvironment of difficult-to-treat solid tumors using living cells programmed to assemble and orchestrate a diverse array of molecules and complex immune pathways. These therapies offer patients the freedom from the apheresis required with each infusion of other cell-based therapies; they also offer more efficient tumor cell killing in a single infusion, reducing the number of infusions and the cell dose and payload.
